Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IO Biomarkers: Where Do We Stand In 2017?

Executive Summary

Survey of recent literature shows breadth and quality of early research activity aimed at developing biomarkers to predict response to PD-1 and CTLA-4 checkpoint inhibitors.

You may also be interested in...



Keytruda Approval Opens New Routes For Immuno-Oncology

Merck's PD-1 inhibitor holds the first cancer indication based on biomarkers rather than tumor location. The most significant market will be colorectal cancer, but Bristol-Myers Squibb's Opdivo is pending for the same subgroup and Roche's Tecentriq could eventually gain a broader approval.

How Immuno-Oncology Is Turning Biomarker Development On Its Head

Immuno-oncology’s challenge is to orchestrate a biomarker program in a highly competitive drug development landscape knowing that prior to having significant clinical experience, the program is unlikely to yield the kinds of binary measurements used to define and select a patient population for a targeted therapy.

Merck’s Oncology Strategy: Digging In With Expansion Of Keytruda

With Keytruda, Merck has shown it has the wherewithal to compete in immuno-oncology against more experienced rivals. Now, as management outlined at ASCO, the company is digging its heels into the field, studying Keytruda in 30 tumor types and evaluating other early stage assets.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel